LI
Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
$4.07 +9.61% (+$0.36)
1M -22.06%
Market Cap $4.89M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 16.26x
PEG N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor Asset turnover 0.00x
ROIC 225.12%
ROA 367.93%
Debt
10 /100
High Int. coverage -291.82x
Debt/Equity 4.80x
Current ratio 1.12x
Stability
37 /100
Moderate Profitable years 0
Beta 0.71x
EPS volatility 79.63%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LIMN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chris Kim
Employees
1
Headquarters
Cerritos